- Home
- TCBS vs ICCM Comparison
TCBS vs ICCM Comparison
Compare TCBS & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | TCBS | ICCM |
|---|---|---|
| Founded | 1934 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.3M | 45.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TCBS | ICCM |
|---|---|---|
| Price | $16.00 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 4.0K | ★ 423.9K |
| Earning Date | 11-07-2025 | 11-19-2025 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $15,268,000.00 | $2,975,000.00 |
| Revenue This Year | N/A | $2.92 |
| Revenue Next Year | N/A | $57.81 |
| P/E Ratio | $18.44 | ★ N/A |
| Revenue Growth | ★ 54.88 | N/A |
| 52 Week Low | $14.85 | $0.59 |
| 52 Week High | $19.40 | $1.66 |
Technical Indicators
Market Signals| Indicator | TCBS | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 46.69 |
| Support Level | $15.90 | $0.68 |
| Resistance Level | $15.95 | $0.75 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 96.15 | 82.25 |
Price Performance
Historical ComparisonAbout TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.